Group 1 - The company, PwC and Shun (01358), announced a share buyback plan, intending to repurchase 460,000 shares at a cost of HKD 644,000 [1]

Core Viewpoint - PwC Holdings (01358.HK) announced a share buyback on September 2, spending HKD 644,000 to repurchase 460,000 shares at a price range of HKD 1.40 to HKD 1.41 per share [1] Summary by Category - **Company Actions** - The company executed a buyback of 460,000 shares, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 644,000, reflecting the company's strategy to manage its capital structure [1] - **Share Price Information** - The repurchase price per share ranged from HKD 1.40 to HKD 1.41, which may suggest the company's valuation perspective on its own shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年9月2日 FF305 確認 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4 ...

普华和顺回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.09.01 | 320.00 | 1.450 | 1.400 | 456.86 | | 2025.07.29 | 140.00 | 1.450 | 1.420 | 201.78 | | 2025.07.22 | 237.10 | 1.480 | 1.420 | 346.75 | | 2025.07.14 | 64.20 | 1.380 | 1.360 | 88.20 | 证券时报·数据宝统计，普华和顺在港交所公告显示，9月1日以每股1.400港元至1.450港元的价格回购 320.00万股，回购金额达456.86万港元。该股当日收盘价1.400港元，下跌2.78%，全天成交额903.61万 港元。 今年以来该股累计进行4次回购，合计回购761.30万股，累计回购金额1093.58万港元。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） ...

Group 1 - The company PwC Holdings (01358.HK) announced a share buyback on September 1, spending HKD 4.57 million to repurchase 3.2 million shares [1] - The buyback price per share ranged from HKD 1.40 to HKD 1.45 [1]

智通财经APP讯，普华和顺(01358)发布公告，于2025年9月1日斥资456.86万港元回购股份320万股，每 股回购价格为1.4-1.45港元。 ...

普华和顺(01358)发布公告，于2025年9月1日斥资456.86万港元回购股份320万股，每股回购价格为1.4- 1.45港元。 ...

| | | FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年9月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | ...

Group 1 - The company reported a revenue increase of 22.4% year-on-year, reaching approximately RMB 414 million for the six months ending June 30, 2025 [1][2] - The company's profit decreased by 7.5% year-on-year to approximately RMB 86.6 million during the same period [1] - Profit attributable to the owners of the company fell by 6.0% year-on-year to approximately RMB 66 million [1] - The board declared an interim dividend of HKD 0.044 per share for the six months ending June 30, 2025, compared to HKD 0.045 per share for the same period in 2024 [1]

Core Viewpoint - PwC announced its mid-year results for 2025, showing a revenue increase driven by strong sales in blood purification and the introduction of revenue from regenerative medical biomaterials, despite a decline in infusion device sales [1] Financial Performance - Revenue reached approximately 414 million HKD, representing a year-on-year increase of 22.4% [1] - Profit attributable to shareholders was about 66 million HKD, reflecting a year-on-year decrease of 6.0% [1] - Earnings per share were reported at 4.44 HKD, with an interim dividend of 4.4 HKD per share [1] Business Segments - The growth in revenue was primarily attributed to robust sales in the blood purification business [1] - The regenerative medical biomaterials segment recorded its first revenue, contributing to overall growth [1] - The decline in sales from the infusion device business partially offset the revenue gains from other segments [1] Profitability Factors - The decrease in net profit was mainly due to reduced operating profit and financial income [1]